Money News with Scott Haywood and Paul Rennie

Great to see Paradigm Biopharmaceuticals’ Executive Chair, Paul Rennie, featured on Money News with Scott Haywood on Wednesday, 1 April.

The discussion highlighted the continued momentum of our Phase 3 osteoarthritis program, with 50% of patients now dosed in PARA_OA_012, a key milestone as the study progresses toward interim analysis.

This interim readout represents a significant value inflection point.

With osteoarthritis affecting over 600 million people globally, current treatment options remain limited, primarily focused on symptom management rather than addressing the underlying disease.

We appreciate the opportunity to engage with the market and continue building awareness of both the burden of OA and Paradigm’s potential to deliver a meaningful therapeutic option.